Antibody drug conjugate and application thereof
By designing linkers and linker-payloads with specific structures, the excellent performance of antibody drug conjugates is solved, and the insufficient performance of existing antibody drug conjugates in the treatment of tumors is achieved, and the precise binding and reduction of tumor cells on normal cells is achieved, which enhances the therapeutic effect and safety.
Patent Information
- Application Number
- CN202411345425.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-09-26
- Publication Date
- 2025-03-28
AI Technical Summary
Although existing antibody drug conjugates have high specificity and killer activity in the treatment of tumors, the available options are still limited and there are many shortcomings in performance.
By designing linkers and linker-payloads for specific structures, an antibody drug conjugate with excellent performance is constructed. The conjugate comprises an antibody or an antigen-binding fragment thereof coupled to a cytotoxic agent such as eriprin or its derivative, isatechan or its derivative) through a linker.
The excellent performance of antibody drug conjugates in many aspects has been achieved, including improving the precise binding of tumor cells and reducing the impact on normal cells, thereby enhancing the therapeutic effect and safety.